BVF PARTNERS L P/IL Insider Trading $XENE Xenon Pharmaceuticals Inc.
Get free email notifications about insider trading for BVF PARTNERS L P/IL.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of BVF PARTNERS L P/IL. BVF PARTNERS L P/IL is in Capstone Therapeutics Corp. ($CAPS) and 10% Owner in CTI BIOPHARMA CORP ($CTIC) and Director in CTI BIOPHARMA CORP ($CTIC) and 10% Owner in XOMA Corp ($XOMA) and Director in XOMA Corp ($XOMA) and 10% Owner in ARQULE INC ($ARQL) and 10% Owner in INFINITY PHARMACEUTICALS, INC. ($INFI) and in FIVE PRIME THERAPEUTICS, INC. ($FPRX) and 10% Owner in FIVE PRIME THERAPEUTICS, INC. ($FPRX) and in CYTOKINETICS INC ($CYTK) and 10% Owner in CYTOKINETICS INC ($CYTK) and 10% Owner in GLYCOMIMETICS INC ($GLYC) and 10% Owner in CONCERT PHARMACEUTICALS, INC. ($CNCE) and 10% Owner in Syndax Pharmaceuticals Inc ($SNDX) and in Eledon Pharmaceuticals, Inc. ($NVUS) and in ChemoCentryx, Inc. ($CCXI) and 10% Owner in ChemoCentryx, Inc. ($CCXI) and 10% Owner in IMMUNE DESIGN CORP. ($IMDZ) and 10% Owner in Calithera Biosciences, Inc. ($CALA) and 10% Owner in Principia Biopharma Inc. ($PRNB) and 10% Owner in PIERIS PHARMACEUTICALS, INC. ($PIRS) and 10% Owner in Xenon Pharmaceuticals Inc. ($XENE) and 10% Owner in Nivalis Therapeutics, Inc. ($NVLS) and 10% Owner in Merus N.V. ($MRUS) and in IDEAYA Biosciences, Inc. ($IDYA) and 10% Owner in IDEAYA Biosciences, Inc. ($IDYA) and Director in Rain Therapeutics Inc. ($RAIN) and Director in Olema Pharmaceuticals, Inc. ($OLMA) and Director in Kymera Therapeutics, Inc. ($KYMR).
BVF PARTNERS L P/IL in Xenon Pharmaceuticals Inc.
Trading Symbol: XENEIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of BVF PARTNERS L P/IL: 10% Owner
Holdings: 336,468 shares
Current Value: $2,759,038
Latest Transaction: Mar 29 2018
$XENE Market Capitalization: $145.83M
$XENE Previous Close: $8.20
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of BVF PARTNERS L P/IL in Xenon Pharmaceuticals Inc.
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ALPN, ARQL, CALA, CAPS, CCXI, CNCE, CTIC, CYTK, ELDN, FPRX, GLYC, IDYA, IMDZ, INFI, KYMR, MRUS, OLMA, PIRS, PRNB, RAIN, SNDX, XENE, XOMA
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 29 2018 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | J | 0.00 | 238,000 | 0 | 238,000 | |
Mar 29 2018 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | J | 0.00 | 861,000 | 0 | 861,000 | |
Mar 29 2018 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | J | 0.00 | 1,338,000 | 0 | 1,338,000 | |
Mar 29 2018 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Sell | J | 0.00 | 238,000 | 0 | 59,464 | 297.5 K to 59.5 K (-80.01 %) |
Mar 29 2018 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Sell | J | 0.00 | 861,000 | 0 | 216,694 | 1.1 M to 216.7 K (-79.89 %) |
Mar 29 2018 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Sell | J | 0.00 | 1,338,000 | 0 | 336,468 | 1.7 M to 336.5 K (-79.91 %) |
Aug 16 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.41 | 7,429 | 17,920 | 1,077,694 | 1.1 M to 1.1 M (+0.69 %) |
Aug 16 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.41 | 11,429 | 27,569 | 1,674,468 | 1.7 M to 1.7 M (+0.69 %) |
Aug 16 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.70 | 13,337 | 36,058 | 1,070,265 | 1.1 M to 1.1 M (+1.26 %) |
Aug 16 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.70 | 28,007 | 75,720 | 1,663,039 | 1.6 M to 1.7 M (+1.71 %) |
Jun 29 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.00 | 8,496 | 33,984 | 297,464 | 289 K to 297.5 K (+2.94 %) |
Jun 29 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.00 | 30,170 | 120,680 | 1,056,928 | 1 M to 1.1 M (+2.94 %) |
Jun 29 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.00 | 46,795 | 187,180 | 1,635,032 | 1.6 M to 1.6 M (+2.95 %) |
Jun 23 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.00 | 854 | 3,416 | 288,968 | 288.1 K to 289 K (+0.30 %) |
Jun 23 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.00 | 2,884 | 11,536 | 1,026,758 | 1 M to 1 M (+0.28 %) |
Jun 23 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.00 | 4,525 | 18,100 | 1,588,237 | 1.6 M to 1.6 M (+0.29 %) |
Jun 23 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.00 | 1,362 | 5,448 | 288,114 | 286.8 K to 288.1 K (+0.47 %) |
Jun 23 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.00 | 4,406 | 17,624 | 1,023,874 | 1 M to 1 M (+0.43 %) |
Jun 23 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.00 | 6,380 | 25,520 | 1,583,712 | 1.6 M to 1.6 M (+0.40 %) |
Jun 19 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.85 | 357 | 1,374 | 286,752 | 286.4 K to 286.8 K (+0.12 %) |
Jun 19 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.85 | 1,271 | 4,893 | 1,019,468 | 1 M to 1 M (+0.12 %) |
Jun 19 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.85 | 1,967 | 7,573 | 1,577,332 | 1.6 M to 1.6 M (+0.12 %) |
Jun 19 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.85 | 1,064 | 4,096 | 286,395 | 285.3 K to 286.4 K (+0.37 %) |
Jun 19 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.85 | 3,873 | 14,911 | 1,018,197 | 1 M to 1 M (+0.38 %) |
Jun 19 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.85 | 6,097 | 23,473 | 1,575,365 | 1.6 M to 1.6 M (+0.39 %) |
Jun 19 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.84 | 1,160 | 4,451 | 285,331 | 284.2 K to 285.3 K (+0.41 %) |
Jun 19 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.84 | 3,845 | 14,753 | 1,014,324 | 1 M to 1 M (+0.38 %) |
Jun 19 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.84 | 6,774 | 25,992 | 1,569,268 | 1.6 M to 1.6 M (+0.43 %) |
Jun 08 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.85 | 20,594 | 79,312 | 284,171 | 263.6 K to 284.2 K (+7.81 %) |
Jun 08 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.85 | 73,749 | 284,022 | 1,010,479 | 936.7 K to 1 M (+7.87 %) |
Jun 08 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.85 | 113,446 | 436,903 | 1,562,494 | 1.4 M to 1.6 M (+7.83 %) |
Jun 08 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.75 | 913 | 3,424 | 263,577 | 262.7 K to 263.6 K (+0.35 %) |
Jun 08 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.75 | 53,260 | 199,725 | 936,730 | 883.5 K to 936.7 K (+6.03 %) |
Jun 08 2017 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.75 | 96,736 | 362,760 | 1,449,048 | 1.4 M to 1.4 M (+7.15 %) |
Page: 1